Press Releases

 Filter by Provider

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heliogen, Inc. (OTC: HLGN) to Zeo Energy Corp. (NasdaqCM: ZEO). Under the terms of the proposed transaction, shareholders of Heliogen will receive shares of Zeo’s Class A common stock valued at approximately $10 million in the aggregate, based on a Zeo Class A common stock price of $1.5859 per share, and subject to an adjustment mechanism based on Heliogen’s net cash at the closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Discover How ProNerve 6 Supports Nerve Health Naturally in 2025 - A Complete Guide to Easing Tingling, Burning, and Numbness Without Prescription

CSGORoll Announces New CS:GO Gambling Game Modes and Bonuses as the Final Phase of Its Successful Q2 2025 Marketing Strategy

Why the Viral Trump "Tariff Sheriff" T-Shirt Is More Than Apparel-It's the Face of Economic Patriotism and the 2025 America First Movement

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders.

Legendary Space, a trailblazer in the Web3 gaming sphere, celebrated the resounding success of its global live premiere for its third flagship game, “Super Lucky Spin,” yesterday, May 30, 2025, at 20:00 (UTC+8). The highly anticipated event was broadcast simultaneously across seven major platforms—Binance Live, X (Twitter), HTX Live, Hotcoin, TikTok, YouTube, and Telegram—drawing an impressive global audience of over 150,000 viewers who witnessed a new chapter in TON-based gaming.

Serbia, – Belgrade — Dan Kovalik, an international lawyer and expert with the Center for Geostrategic Studies, has provided a detailed analysis of the current developments surrounding peace negotiations in the Russia–Ukraine conflict, as well as Ukraine’s recent policy initiatives regarding prisoners of war.

A Plant-Based, Broad-Spectrum CBD Roll-On With 25 Natural Ingredients Offers Targeted Relief for Muscle Tension, Joint Discomfort, and Daily Aches-Without the Risks of Conventional Painkillers

KODIAK, Alaska, May 31, 2025 (GLOBE NEWSWIRE) -- Afognak Native Corporation’s Board of Directors is pleased to announce the hiring of Daniel “Dan” M. Corbett as Chief Executive Officer, leading Afognak into its next phase of growth and business advancement.

MUNICH, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- There was a palpable sense of excitement in Munich as the city prepared to host the UEFA Champions League final between PSG and Inter Milan. Fans from France and Italy – and much further afield – have been gathering in the Bavarian capital for several days.

Sippy cup transition not only developmental milestone, but has nutritional benefits

The law firm of Robbins Geller Rudman & Dowd LLP announces that holders of Broadmark Realty Capital Inc. (NYSE: BRMK) common stock as of the record date of the May 2023 merger between Broadmark and Ready Capital Corporation (NYSE: RC) (“Merger”), have until July 28, 2025 to seek appointment as lead plaintiff of the Broadmark class action lawsuit. Captioned Grant v. Broadmark Realty Capital, No. 25-cv-01013 (W.D. Wash.), the Broadmark class action lawsuit charges Broadmark, Ready Capital, certain of Broadmark’s and Ready Capital’s top executives and directors, and Ready Capital’s external asset manager with violations of the Securities Exchange Act of 1934.

UK-based Ultra Beam Lighting expands its LED soffit downlights range to meet growing demand for stylish, energy-efficient outdoor lighting.

An author known for her captivating storytelling has unveiled her latest work, a novel that explores the nuanced dynamics of workplace romance. This new book delves into the complexities of love and ambition, drawing inspiration from real-life experiences that resonate with many professionals navigating similar situations.

Get ready to experience the theatrical rock spectacle of Ghost’s 2025 Skeletour World Tour! The Grammy-winning Swedish band, known for their provocative lyrics, elaborate live performances, and genre-blending mix of metal, rock, and pop, is hitting arenas across North America, Europe, the UK, and Mexico. If you’re looking to score affordable 2025 Ghost concert tickets, CapitalCityTickets.com is your trusted source for discounted tickets across all seating levels. Use the exclusive promo code CITY10 at checkout to save an additional 10% on your purchase, from floor seats to upper tiers. Here’s everything you need to know about securing cheap Ghost tickets and the full list of 2025 tour dates for this unforgettable live ritual.

Get ready for an unforgettable experience with Dude Perfect’s 2025 Hero World Tour! Known for their jaw-dropping trick shots, hilarious challenges, and high-energy performances, Dude Perfect—Tyler Toney, Cody Jones, Garrett Hilbert, and twins Coby and Cory Cotton—is bringing their unique blend of sports, comedy, and audience engagement to arenas across North America. If you’re looking to score affordable 2025 Dude Perfect tickets, CapitalCityTickets.com is your go-to platform. Use the exclusive promo code CITY10 at checkout to unlock extra savings on all seating levels, from floor seats to upper tiers. Here’s everything you need to know about securing cheap tickets and the 2025 tour dates for this must-see family-friendly show.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - May 31, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy (“Strategy”) ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is July 15, 2025.

Get +11% Extra on Deposit & 1 Free Spin with GGDrop's Exclusive Promo Code "HELLA11"

Read CrazyBulk reviews and discover how their legal steroid alternatives can boost muscle growth, strength, and fat loss. Find out real customer results, product benefits, and how to use CrazyBulk supplements effectively for maximum gains

TALLMADGE, OH / ACCESS Newswire / May 31, 2025 / What You Will Get from This Article:

Soleil River Nation will join students from around the globe for the second time, acclaimed faculty, and celebrated guest artists on Interlochen’s scenic northern Michigan campus for a summer of artistic transformation.

In the world of dive education, instructor training often follows a traditional script—lecture-heavy days, skill demonstrations performed kneeling in the sand, and a heavy emphasis on academic performance rather than real-world instructional capabilities. But at Oceans 5 Gili Air, things are different.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen’s top current and former executives with violations of the Securities Exchange Act of 1934.

Guangzhou, China & Singapore, May 15th, 2025: Heron Intelligent Equipment Ltd. Co. has announced a strategic partnership with Ito Group, which aims to accelerate the sale of Heron technologies in high growth regions, such as USA, Vietnam, India, Thailand, Japan etc. The two companies will collaborate closely to explore synergies, particularly in the fields of metal joining equipment, machinery, integration solutions, and automated production lines.

Discover if NetherexPro's AI-powered trading robot is legit. Read our in-depth 2025 review on its accuracy, performance, security, and real user results!

Discover if Immediate Luminary AI trading robot is safe and effective. Read our in-depth 2025 review to learn features, performance, security, real feedback.

New Delhi, India — In the vibrant heart of India, where ancient traditions intersect with the rise of smart cities and digital infrastructure, global blockchain pioneers gathered for a landmark event: the Rickys Chain Project Conference, hosted by Rickys Foundation. This was more than a meeting — it was a milestone in the movement toward a decentralized, sustainable, and inclusive future.

JERSEYVILLE, IL / ACCESS Newswire / May 31, 2025 / Recently, searches for "Wellnee Brace Reviews" and "Wellnee Knee Brace customers complaints " are soaring, as there are lots of questions such as how it operates, safety advice, whether you should buy this knee brace, pros and cons, among others. This heightened interest necessitated the need for an in-depth Wellnee knee brace review article, everything you would want to know in between.

JERSEYVILLE, IL / ACCESS Newswire / May 31, 2025 / Kerassentials is quickly becoming one of the most talked-about toenail fungus treatment oils, but here's a crucial warning: platforms like Amazon, Walmart, and eBay have listings the official company has identified as counterfeit. That means if you try to order Kerassentials from anywhere other than the official website, you could end up with a fake version containing unknown or unsafe ingredients.

Limo SF VIP (888-888-0195) has announced that they are expanding their luxury transport service with a new fleet of high-end limousines and executive vehicles.

JERSEY CITY, NJ / ACCESS Newswire / May 31, 2025 / Are you in search of the best crypto casinos available in the industry? Then, you are in the right spot! We have come up with a list of the top five best gambling sites with the help of our experts. The details about the crypto gambling sites are given below for your reference.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.

SINGAPORE, SG / ACCESS Newswire / May 31, 2025 / PowerTrade, the market-leading altcoin-options exchange, today announces that its ultra-short-dated 10-minute and 1-hour option contracts are now live for BTC on both the PowerTrade CEX and PowerDEX with zero fees. To make them accessible to every trader, the company is simultaneously rolling out PowerTrade Lite - a streamlined interface where a single click on the chart automatically selects the highest-ROI contract, no option chain or Greeks required.

ispace, inc. (ispace) (TOKYO: 9348), a global lunar exploration company, announced today that the RESILIENCE lunar lander has successfully completed all orbital maneuvers while in lunar orbit and is now being prepared for its landing attempt on June 6, 2025.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147) involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement in overall survival for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The results are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine (NEJM).

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology (ASCO®) press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation (Abstract LBA1000) and have been simultaneously published in the New England Journal of Medicine.

ELKHORN, NE / ACCESS Newswire / May 31, 2025 / United Republic Bank, a trusted community-focused financial institution, has officially launched its new, modern website, designed and developed by OMNICOMMANDER in response to a third party's recent sunset of its website hosting platform. The new site features a sleek, mobile-responsive design, full ADA accessibility, and a user experience tailored to both personal and business clients.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] ≥10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined by an FDA-approved test. KEYTRUDA, when given in combination with Gilead’s TROP2 antibody-drug conjugate (ADC) Trodelvy, resulted in a median progression-free survival (PFS) of 11.2 months versus 7.8 months when KEYTRUDA was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA109) and were selected for the official ASCO Press Program.

High school students who quickly answered tough questions posed to state-championship teams at the Council for Economic Education’s National Economics Challenge (NEC) finals may not change the world today.

Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months vs 7.8 months when Keytruda was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 ASCO Annual Congress (Abstract #LBA109).

Positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab plus paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Results will be presented today as a late-breaking oral presentation (LBA #4002) at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and simultaneously published in The New England Journal of Medicine.